Last reviewed · How we verify

hp-FSH

AZ Jan Palfijn Gent · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

hp-FSH is a Small molecule drug developed by AZ Jan Palfijn Gent. It is currently FDA-approved. Also known as: Menopur.

HP-FSH is a type of fertility treatment used in reproductive endocrinology and fertility studies, often in combination with other interventions such as GnRH agonists or antagonists. HP-FSH is administered as an oligonucleotide, a type of nucleic acid-based treatment.

At a glance

Generic namehp-FSH
Also known asMenopur
SponsorAZ Jan Palfijn Gent
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about hp-FSH

What is hp-FSH?

hp-FSH is a Small molecule drug developed by AZ Jan Palfijn Gent.

Who makes hp-FSH?

hp-FSH is developed and marketed by AZ Jan Palfijn Gent (see full AZ Jan Palfijn Gent pipeline at /company/az-jan-palfijn-gent).

Is hp-FSH also known as anything else?

hp-FSH is also known as Menopur.

What development phase is hp-FSH in?

hp-FSH is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing